...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neoplasma: Journal of Experimental and Clinical Oncology >Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.
【24h】

Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.

机译：血清肝细胞生长因子和白细胞介素6水平可以将原发性或转移性肝肿瘤患者与良性肝病变患者区分开。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hepatocyte growth factor (HGF) is a potent stimulator of angiogenesis and cancer metastasis. Interleukin-6 (IL-6) is a pleiotropic cytokine that can act as an autocrine or paracrine growth factor in various tumor cells. In this study, we investigated the role of serum HGF and IL-6 levels to distinguish primary or metastatic liver tumors from benign liver lesions. Serum HGF and IL-6 levels were measured in 64 cancer patients and 12 healthy controls. Patients were divided into 5 groups: Group-1 (n=24): Breast cancer patients in complete remission without any liver lesion, Group-2 (n=8): Breast cancer patients in complete remission with benign liver lesion, Group-3 (n=10): Breast cancer patients with liver metastasis, Group-4 (n=11): Metastatic breast cancer patients without liver metastasis, Group-5 (n=11): Patients with hepatocellular carcinoma. Group-6 (n=12): Healthy controls. Serum HGF levels were found to be higher in group-5 (606.4+/-255.8 pg/ml) than those in group-1 (*305.6+/-42.3 pg/ml), group-2(*293.9+/-44.8 pg/ml), group-4 (**358.4+/-81.9 pg/ml) and group-6 (*305.8+/-24.9 pg/ml) (*p<0.001, **p<0.05). Patients in group-3 (448.9+/-157.3 pg/ml) had higher serum HGF levels than those in group-1, group-2 and group-6 (p<0.05). Serum IL-6 levels were found to be higher in group-5 (54.9+/-37.4 pg/ml) than those in group-1 (9.7+/-6.4 pg/ml), group-2 (9.5+/-4.8 pg/ml), group-4 (17.6+/-19.6 pg/ml) and group-6 (12.6+/-5.2 pg/ml, p<0.05). Patients in group-3 (32.5+/-36.9 pg/ml) had higher serum IL-6 levels than those in group-1, 2 and group-6, but these were not statistically significant (p>0.05). This study showed that primer and metastatic liver tumors had higher serum HGF and IL-6 levels than other patients and controls. Measurements of these markers in serum may be used to distinguish patients with primer liver tumors or breast cancer patients with liver metastasis from those with benign liver lesions or non-metastatic patients.
机译：肝细胞生长因子（HGF）是血管生成和癌症转移的有效刺激剂。白介素6（IL-6）是一种多效细胞因子，可以在多种肿瘤细胞中充当自分泌或旁分泌生长因子。在这项研究中，我们调查了血清HGF和IL-6水平在区分原发性或转移性肝肿瘤与良性肝病变中的作用。在64位癌症患者和12位健康对照中测量了血清HGF和IL-6水平。患者分为5组：第1组（n = 24）：完全缓解且无任何肝脏病变的乳腺癌患者，第2组（n = 8）：完全缓解且有良性肝病变的乳腺癌患者，第3组（n = 10）：患有肝转移的乳腺癌患者，第4组（n = 11）：无肝转移的转移性乳腺癌患者，第5组（n = 11）：患有肝细胞癌的患者。第6组（n = 12）：健康对照。发现第5组的血清HGF水平高于第1组（* 305.6 +/- 42.3 pg / ml），第2组的血清HGF水平（* 305.6 +/- 42.3 pg / ml）（* 293.9 +/- 44.8） pg / ml），第4组（** 358.4 +/- 81.9 pg / ml）和第6组（* 305.8 +/- 24.9 pg / ml）（* p <0.001，** p <0.05）。第三组（448.9 +/- 157.3 pg / ml）的患者血清HGF水平高于第一，第二和第六组（p <0.05）。发现第5组的血清IL-6水平较高（54.9 +/- 37.4 pg / ml），高于第1组的血清IL-6（9.7 +/- 6.4 pg / ml）和第2组的（9.5 +/- 4.8） pg / ml），第4组（17.6 +/- 19.6 pg / ml）和第6组（12.6 +/- 5.2 pg / ml，p <0.05）。第三组（32.5 +/- 36.9 pg / ml）的患者血清IL-6水平高于第一，第二和第六组，但无统计学意义（p> 0.05）。这项研究表明，引物和转移性肝肿瘤的血清HGF和IL-6水平高于其他患者和对照。血清中这些标记物的测量可用于区分患有引物肝肿瘤的患者或患有肝转移的乳腺癌患者与良性肝病变的患者或非转移性患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号